An observational study in Paraneoplastic Neurological Syndromes, sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Heinrich-Heine University, Duesseldorf · Observational
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients.
Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
227 studies on the registry are indexed under Neoplastic Cells, Circulating; 54 are open to participants now.
This study's planned enrollment of 60 is below the median of 120 across 121 observational studies indexed under Neoplastic Cells, Circulating.
Browse Neoplastic Cells, Circulating studies →Heinrich-Heine University, Duesseldorf is the lead sponsor of 180 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will include patients with paraneoplastic neurological syndromes (PNS) and matched tumor patients without PNS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies with a detectable tumor
Diagnostic Test: CTC & ctDNA analysis
PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor
Diagnostic Test: CTC & ctDNA analysis
Tumor patients without PNS
Diagnostic Test: CTC & ctDNA analysis
Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood
CTC detection
Detection of circulating tumor cells (CTCs) in the peripheral blood
Time frame: Time of enrollment (BL)
ctDNA detection
Detection of circulating tumor DNA (ctDNA) in serum
Time frame: Time of enrollment (BL)
CTC mutation profile
Mutations in oncogenes and tumor suppressor genes
Time frame: Time of CTC analysis (BL)
Plan to share: Yes — All pseudonymized IPD that underlie the results in a publication.
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2030, 91 months after the start.
Of 59 observational studies under Neoplastic Cells, Circulating, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 38. This study's planned 91 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Cells, Circulating →
Heinrich-Heine University, Duesseldorf →